因此,应该避免这种中期分析。
根据计划,当中期分析显示索拉非尼的效果明显优于安慰剂时,研究会过早的中止。
The study was stopped prematurely when a planned interim analysis showed sorafenib's significant superiority over placebo.
此分析应当清楚地表明短期、中期和长期的成本优势。
This analysis should clearly show the short -, medium -, and long-term cost benefits.
应用推荐